CN112195173A - Method for fusing myocardial cells and tumor cells - Google Patents
Method for fusing myocardial cells and tumor cells Download PDFInfo
- Publication number
- CN112195173A CN112195173A CN202011100153.5A CN202011100153A CN112195173A CN 112195173 A CN112195173 A CN 112195173A CN 202011100153 A CN202011100153 A CN 202011100153A CN 112195173 A CN112195173 A CN 112195173A
- Authority
- CN
- China
- Prior art keywords
- cells
- tumor
- tumor cells
- myocardial
- fusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/166—Animal cells resulting from interspecies fusion
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention belongs to the field of biotechnology, and particularly relates to a method for fusing myocardial cells and tumor cells. The fusion method is to selectively fuse myocardial cells and tumor cells to improve the fusion rate of the myocardial cells and the tumor cells. The invention aims to improve the fusion rate by selectively fusing myocardial cells and tumor cells. After the fusion, the tumor cell has or partially has the character that the cardiac muscle cell is highly differentiated and can not be regenerated, so that the tumor cell can grow slowly, and the purpose of inhibiting the growth and the metastasis of the tumor cell can be achieved.
Description
The technical field is as follows:
the invention belongs to the field of biotechnology, and particularly relates to a method for fusing myocardial cells and tumor cells.
Background art:
cell fusion is the fusion of two cells or protoplasts under spontaneous or artificial induction to form a hybrid cell, and the new cell has new genetic and biological properties. When the cell is fused, the filial cell has great difference with the parent cell, and the filial cell obtains the characteristics of parents after the cell is fused. Cell fusion plays an important role in the physiological and pathological processes of the body, and is highly related to embryonic development, body growth, tissue healing, inflammation and tumor.
The development, growth and metastasis of tumors are all involved in cell fusion. Tumors take part in various processes of tumor metastasis by cell fusion, and change self characteristics through cell fusion, thereby influencing self biological behaviors. Meanwhile, in the process of generating and developing the tumor, the tumor cells are fused with surrounding cells to carry out signal transmission with a tumor microenvironment, so that the generation and development of the tumor are promoted.
When the tumor is transferred, the tumor cells are separated from the primary focus, and reach other parts of the body through ways of lymph, blood vessels or body cavities and the like and continue to grow. Most tumor cells have the potential and tendency of fusion, and the cell fusion can increase the polymorphism of the tumor cells and the malignancy degree of the filial generation cells, so that the filial generation cells have stronger proliferation, metastasis, anti-apoptosis capability and drug resistance. The fusion of different types of somatic cells such as lesion tissue cells, macrophages, leukocytes, lymphocytes, endothelial cells and the like with tumor cells can directly or indirectly promote the metastasis of the tumor cells.
The cardiomyocytes are also called myocardial fibers and have the ability to stimulate and contract. Adult cardiomyocytes do not have a regenerative capacity as terminally differentiated cells. The tumor cell essence is the tumor, has the basic characteristics of immortality, mobility, loss of contact inhibition and the like, and the organism loses the normal regulation and control on the growth of the tumor cell, so that the tumor cell abnormally proliferates, grows rapidly and destroys the normal organ structure. The tumor cells are not controlled by a normal growth regulation system, and can continuously divide and proliferate, so that the cancer is difficult to cure and has obvious metastasis tendency.
The high differentiation of the cardiac muscle cell can not be regenerated, the tumor cell can grow without limit, the cardiac muscle cell and the tumor cell are fused, the generated hybrid cell has the characteristics of two cells, namely, the hybrid cell has or partially has the non-renewable property of the cardiac muscle cell, the growth and the propagation of the tumor cell can be slowed down, and the fusion probability of the tumor cell and other somatic cells is greatly reduced after the cardiac muscle cell and the tumor cell are fused by adopting an inducer. The main means of modern medicine for treating cancer are medicine, operation and radiotherapy, which aim to kill off tumor cells and have the same harm to human body, and the main means of modern medicine is to kill off tumor cells and have the same effect on normal cells, so that the growth rate of tumor cells is hoped to be slowed down by a cell fusion method at present.
However, cell fusion is random, and any 2 cells contacted with the cell fusion into one cell in the presence of an inducer is possible. Therefore, there is an urgent need to develop a method for reducing tumor growth after fusion.
The invention content is as follows:
the purpose of the invention is as follows:
the invention aims to provide a method for fusing a myocardial cell and a tumor cell, and aims to improve the fusion rate through selective fusion of the myocardial cell and the tumor cell. After the fusion, the tumor cell has or partially has the character that the cardiac muscle cell is highly differentiated and can not be regenerated, so that the tumor cell can grow slowly, and the aim of inhibiting the growth of the tumor cell is fulfilled.
The technical scheme is as follows:
a method for fusing myocardial cell with tumor cell features that the myocardial cell and tumor cell are selectively fused to increase the fusion rate of myocardial cell and tumor cell.
Furthermore, the myocardial cells are firstly non-specifically adsorbed and combined with tumor cell antibodies, and then are fused with the tumor cells, and finally fused cells are obtained.
Further, the specific method of fusion comprises: preparing purified myocardial cells for the obtained heart tissues, and preparing, purifying and collecting tumor cells;
firstly adsorbing the myocardial cells and the tumor cell antibody on the non-specific surface, then adding the purified and collected tumor cells for mixing, and finally obtaining fused cells.
Further, the myocardial cells and the tumor cells were suspended in a phosphate buffer solution at a cell density of 1X105/ml～1×107/ml。
Further, the specific steps of nonspecific surface adsorption of antibodies of the myocardial cells and the tumor cells comprise: will be 1 × 105/ml～1×107Placing the myocardial cell solution in a centrifuge tube, wherein the total number of cells is not more than 5 × 107Adjusting the pH value to 7.8-8.4 by using a potassium carbonate solution, slowly adding 0.1-0.5 mg of an antibody of the tumor antigen, and oscillating for 15-30 minutes at 36-40 ℃; centrifuging at 1500rpm for 5-15 minutes at room temperature, discarding the supernatant, and resuspending with phosphate buffer.
Further, the specific steps of fusing with tumor cells include: adding tumor cells with the number ratio of the myocardial cells to the myocardial cells being 1 (1-5) into a centrifugal tube for mixing the myocardial cells and the tumor antigen antibodies, wherein the total number of the cells is not more than 2 multiplied by 108Uniformly mixing, centrifuging at room temperature at 1500rpm for 5-15 minutes, removing supernatant, and placing the centrifuge tube in a water bath at 36-40 ℃ for 3-5 minutes; placing a 50% polyethylene glycol solution with the molecular weight of 1000-4000 in a water bath, preheating to 36-40 ℃, quickly adding 200-1000 microliter of the polyethylene glycol solution into a centrifuge tube containing two kinds of cells within one minute, uniformly mixing the cells, placing the centrifuge tube in a 36-40 ℃ water bath for 3-5 minutes, and then adding 0.5-1.5 ml of phosphate buffer solution within 1 minute to terminate the reaction;
and adding 30-50 ml of phosphate buffer solution within 3-5 minutes, uniformly mixing, centrifuging at 1500rpm for 5-15 minutes at room temperature, discarding the supernatant, adding 30-50 ml of phosphate buffer solution again, uniformly mixing, centrifuging at 1500rpm for 5-15 minutes at room temperature, discarding the supernatant, adding 0.2-2 ml of phosphate buffer solution, and re-suspending the cells to obtain fused cells.
Furthermore, the cardiac muscle cell refers to cardiac muscle cells of human, pig, dog, rabbit, sheep, rat and mouse, and the tumor cell refers to tumor cells of any tissue of human body.
Furthermore, the tumor cell antibody is a corresponding antibody prepared by taking any kind of tumor antigens of human bodies as antigens and adopting a biological engineering technology.
The advantages and effects are as follows:
compared with the prior art, the invention has the following advantages:
cell fusion was observed by staining cardiomyocytes and tumor cells and counting under a microscope after fusion. The fusion rate of the myocardial cells and the tumor cells is increased to about 40-60% by adopting the method, and the fusion rate is greatly increased.
Description of the drawings:
FIG. 1 is a graph showing the effect test.
The specific implementation mode is as follows:
the core of the invention is to inhibit and slow down the growth rate of the tumor cells by fusing the myocardial cells and the tumor cells. Because cell fusion is random, it is possible that any 2 cells contacted will fuse into one cell in the presence of an inducing agent. After the cardiomyocytes and tumor cells are mixed, fusion can occur between the cardiomyocytes and cardiomyocytes, between the tumor cells and tumor cells, and between the cardiomyocytes and tumor cells, but it is desirable that the cardiomyocytes and tumor cells are fused. In order to improve the fusion rate of the myocardial cells and the tumor cells, the antibodies of the myocardial cells and the tumor antigens are combined, namely the tumor antibodies are non-specifically adsorbed on the surfaces of the myocardial cells, and after the antibodies are mixed with the tumor cells, the tumor antibodies adsorbed on the surfaces of the myocardial cells are specifically combined with the antigens on the tumor cells, so that the myocardial cells can be tightly connected with the tumor cells, the fusion can be carried out under the action of an inducer, and the fusion rate of the myocardial cells and the tumor cells is greatly improved.
The invention researches the selective fusion method of the myocardial cells and the tumor cells and improves the fusion rate. The fused tumor cells have the property of being undifferentiated by the myocardial cells, grow slowly, can greatly inhibit the growth and the metastasis of the tumor cells, and lay the research foundation for the new method for researching the tumor treatment. At present, no study on the fusion of myocardial cells and tumor cells is reported.
The present invention will be described in further detail with reference to examples, but the scope of the present invention is not limited by the examples.
Example 1
Collecting human heart tissue, separating and purifying to obtain cardiomyocytes, and making the cardiomyocytes into cells with density of 5x105The suspension/ml, 5ml was put into a centrifuge tube, adjusted to pH 8.0 with potassium carbonate solution, 0.2mg of mouse anti-human CEA antibody was slowly added thereto, and shaken at 38 ℃ for 20 minutes. Centrifugation was carried out at 1500rpm for 10 minutes at room temperature, and the supernatant was discarded and resuspended in phosphate buffer.
Adding lung cancer tumor cells into the centrifuge tube according to the quantity ratio of tumor cells to myocardial cells of 1:2, uniformly mixing, centrifuging at 1500rpm at room temperature for 10 minutes, removing supernatant, and placing the centrifuge tube in water at 38 ℃ for 5 minutes; after 50% polyethylene glycol solution with molecular weight of 4000 is placed in a water bath and preheated to 38 ℃, 1000 microliter of polyethylene glycol solution is quickly added into the centrifuge tube containing the two cells within 1 minute, the cells are uniformly mixed, the centrifuge tube is placed in a water bath with the temperature of 38 ℃ for 5 minutes, and then 1ml of phosphate buffer solution is added within 1 minute to stop the reaction. And adding 30ml of phosphate buffer solution within 5 minutes, uniformly mixing, centrifuging at the room temperature of 1500rpm for 10 minutes, discarding the supernatant, adding 30ml of phosphate buffer solution again, uniformly mixing, centrifuging at the room temperature of 1500rpm for 10 minutes, discarding the supernatant, adding 2ml of phosphate buffer solution, and re-suspending the cells to obtain fused cells.
Example 2
Collecting human heart tissue, separating and purifying to obtain myocardial cells, and making the myocardial cells into cells with density of 1x106The suspension of 5ml was put into a centrifuge tube, adjusted to pH 8.0 with potassium carbonate solution, slowly added with 0.2mg rabbit anti-human AFP antibody and shaken at 38 ℃ for 30 minutes. Centrifugation was carried out at 1500rpm for 10 minutes at room temperature, and the supernatant was discarded and resuspended in phosphate buffer.
Adding the liver cancer tumor cells into the centrifuge tube according to the quantity ratio of the tumor cells to the myocardial cells of 1:3, uniformly mixing, centrifuging at 1500rpm at room temperature for 10 minutes, removing supernatant, and placing the centrifuge tube in water at 38 ℃ for 5 minutes; after 50% polyethylene glycol solution with molecular weight of 4000 is placed in a water bath and preheated to 38 ℃, 1000 microliter of polyethylene glycol solution is quickly added into the centrifuge tube containing the two cells within 1 minute, the cells are uniformly mixed, the centrifuge tube is placed in a water bath with the temperature of 38 ℃ for 5 minutes, and then 1ml of phosphate buffer solution is added within 1 minute to stop the reaction. And adding 30ml of phosphate buffer solution within 5 minutes, uniformly mixing, centrifuging at the room temperature of 1500rpm for 10 minutes, discarding the supernatant, adding 30ml of phosphate buffer solution again, uniformly mixing, centrifuging at the room temperature of 1500rpm for 10 minutes, discarding the supernatant, adding 2ml of phosphate buffer solution, and re-suspending the cells to obtain fused cells.
Example 3
Preparing purified myocardial cells from animal heart tissue or human heart tissue, simultaneously preparing, purifying and collecting tumor cells, respectively suspending the two cells with phosphate buffer solution at a cell density of 1x105/ml～1x107And/ml. Preparing polyethylene glycol with the molecular weight of 1000-4000 into a solution with the concentration of 40-60%, and adjusting the pH value to 8.0-8.4.
Non-specific surface adsorption of myocardial cells and tumor antibody by 1x105/ml～1x107Putting the myocardial cell solution in a centrifuge tube, wherein the total number of cells is not more than 5x107And/ml, adjusting pH to 8.0 with potassium carbonate solution, slowly adding 0.1-0.5 mg tumor antigen antibody (such as CEA antibody, AFP antibody, etc.), and shaking at 38 deg.C for 15-30 min. Centrifugation was carried out at 1500rpm for 10 minutes at room temperature, and the supernatant was discarded and resuspended in phosphate buffer.
Adding the tumor cells into the centrifuge tube according to the quantity ratio of the tumor cells to the myocardial cells of 1 (1-5), wherein the total number of the cells is not more than 2x108Mixing the materials and the solution uniformly, centrifuging the mixture at 1500rpm for 5 to 15 minutes at room temperature, removing supernatant, and placing the centrifugal tube in a 38 ℃ water bath for 3 to 5 minutes; placing 50% polyethylene glycol solution with the molecular weight of 1000-4000 in a water bath, preheating to 38 ℃, quickly adding 200-1000 mul into the centrifuge tube containing the two cells within 1 minute, uniformly mixing the cells, placing the centrifuge tube in a 38 ℃ water bath for 3-5 minutes, and then adding 1ml of phosphate buffer solution within 1 minute to stop the reaction. Within 3-5 minutesAdding 30-50 ml of phosphate buffer solution, uniformly mixing, centrifuging at 1500rpm for 5-15 minutes at room temperature, discarding the supernatant, adding 30-50 ml of phosphate buffer solution again, uniformly mixing, centrifuging at 1500rpm for 5-15 minutes at room temperature, discarding the supernatant, adding 0.2-2 ml of phosphate buffer solution, and re-suspending the cells to obtain fused cells.
FIG. 1 is a graph showing the effect of the present invention on staining mouse cardiomyocytes and human hepatoma cells HepG2 with fluorescent tracers CMFDA and CMTMR, respectively. Wherein, the picture a is a fluorescence picture of mouse myocardial cells after being stained by CMTMR after being amplified by 100 times; FIG. b is a fluorescence image of human hepatoma cell HepG2 stained by CMFDA after 100-fold amplification; FIG. c is a fluorescence image of human liver cancer cell HepG2 and mouse cardiac muscle cell fused by the technology after 100 times of amplification; FIG. d shows the state of the fused cells after 24 hours of culture, and the rupture phenomenon has occurred.
Cell fusion was observed by staining cardiomyocytes and tumor cells and counting under a microscope after fusion. The fusion rate of the myocardial cells and the tumor cells is about 15-30% by adopting a conventional polyethylene glycol induction method, and the fusion rate of the myocardial cells and the tumor cells is improved to about 40-60% by adopting the method.
Claims (8)
1. A method of fusing a cardiomyocyte and a tumor cell, comprising: the myocardial cells and the tumor cells are selectively fused, so that the fusion rate of the myocardial cells and the tumor cells is improved.
2. The method of claim 1, wherein the fusion of cardiomyocytes and tumor cells is performed by: the myocardial cells are firstly combined with the tumor cell antibody in a non-specific adsorption way and then fused with the tumor cells, and finally, fused cells are obtained.
3. The method of claim 1 or 2, wherein the fusion of cardiomyocytes and tumor cells is performed by: the specific method for fusion comprises the following steps:
preparing purified myocardial cells for the obtained heart tissues, and preparing, purifying and collecting tumor cells;
firstly adsorbing the myocardial cells and the tumor cell antibody on the non-specific surface, then adding the purified and collected tumor cells for mixing, and finally obtaining fused cells.
4. The method of claim 3, wherein the fusion of cardiomyocytes and tumor cells is performed by: suspending myocardial cells and tumor cells with phosphate buffer solution at cell density of 1 × 105/ml～1×107/ml。
5. The method of claim 1 or 2, wherein the fusion of cardiomyocytes and tumor cells is performed by: the specific steps of the nonspecific surface adsorption of the antibody of the myocardial cells and the tumor cells comprise:
will be 1 × 105/ml～1×107Placing the myocardial cell solution in a centrifuge tube, wherein the total number of cells is not more than 5 × 107Adjusting the pH value to 7.8-8.4 by using a potassium carbonate solution, slowly adding 0.1-0.5 mg of an antibody of the tumor antigen, and oscillating for 15-30 minutes at 36-40 ℃; centrifuging at 1500rpm for 5-15 minutes at room temperature, discarding the supernatant, and resuspending with phosphate buffer.
6. The method of claim 1 or 2, wherein the fusion of cardiomyocytes and tumor cells is performed by: the specific steps of the fusion with the tumor cells comprise:
adding tumor cells with the number ratio of the myocardial cells to the myocardial cells being 1 (1-5) into a centrifugal tube for mixing the myocardial cells and the tumor antigen antibodies, wherein the total number of the cells is not more than 2 multiplied by 108Uniformly mixing, centrifuging at room temperature at 1500rpm for 5-15 minutes, removing supernatant, and placing the centrifuge tube in a water bath at 36-40 ℃ for 3-5 minutes; placing a 50% polyethylene glycol solution with the molecular weight of 1000-4000 in a water bath, preheating to 36-40 ℃, quickly adding 200-1000 microliter of the polyethylene glycol solution into a centrifuge tube containing two kinds of cells within one minute, uniformly mixing the cells, placing the centrifuge tube in a 36-40 ℃ water bath for 3-5 minutes, and then adding 0.5-1.5 ml of phosphate buffer solution within 1 minute to terminate the reaction;
and adding 30-50 ml of phosphate buffer solution within 3-5 minutes, uniformly mixing, centrifuging at 1500rpm for 5-15 minutes at room temperature, discarding the supernatant, adding 30-50 ml of phosphate buffer solution again, uniformly mixing, centrifuging at 1500rpm for 5-15 minutes at room temperature, discarding the supernatant, adding 0.2-2 ml of phosphate buffer solution, and re-suspending the cells to obtain fused cells.
7. The method of claim 1 or 2, wherein the fusion of cardiomyocytes and tumor cells is performed by: the myocardial cells refer to myocardial cells of human, pig, dog, rabbit, sheep, rat and mouse, and the tumor cells refer to tumor cells of any tissues of human body.
8. The method of claim 1 or 2, wherein the fusion of cardiomyocytes and tumor cells is performed by: the tumor cell antibody is a corresponding antibody prepared by taking any kind of tumor antigens of human bodies as antigens and adopting a biological engineering technology.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019111703732 | 2019-11-26 | ||
| CN201911170373 | 2019-11-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112195173A true CN112195173A (en) | 2021-01-08 |
Family
ID=74008678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011100153.5A Pending CN112195173A (en) | 2019-11-26 | 2020-10-15 | Method for fusing myocardial cells and tumor cells |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112195173A (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995016775A1 (en) * | 1993-12-14 | 1995-06-22 | Yajun Guo | Tumor cell fusions and methods for use of such tumor cell fusions |
| JPH1048151A (en) * | 1996-08-02 | 1998-02-20 | Nkk Corp | Method for detecting surface flaw |
| US20070212338A1 (en) * | 2000-01-11 | 2007-09-13 | Greenville Hospital System | Hybrid cells |
| CN101519649A (en) * | 2009-01-22 | 2009-09-02 | 上海交通大学 | Hybridoma strain and preparation method thereof |
| CN102827826A (en) * | 2012-09-11 | 2012-12-19 | 赵永祥 | Method for inducing dendritic cells and tumour cells to fuse |
| CN105063013A (en) * | 2015-09-02 | 2015-11-18 | 北京多赢时代科技有限公司 | Fusion cell, preparation method of fusion cell and application of fusion cell as tumor vaccine |
| CN105316313A (en) * | 2015-11-03 | 2016-02-10 | 重庆市畜牧科学院 | Efficient cell fusion method |
| CN108315319A (en) * | 2018-02-05 | 2018-07-24 | 翁炳焕 | A kind of cell fusion method of CD138 monoclonal antibodies target capture |
-
2020
- 2020-10-15 CN CN202011100153.5A patent/CN112195173A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995016775A1 (en) * | 1993-12-14 | 1995-06-22 | Yajun Guo | Tumor cell fusions and methods for use of such tumor cell fusions |
| JPH1048151A (en) * | 1996-08-02 | 1998-02-20 | Nkk Corp | Method for detecting surface flaw |
| US20070212338A1 (en) * | 2000-01-11 | 2007-09-13 | Greenville Hospital System | Hybrid cells |
| CN101519649A (en) * | 2009-01-22 | 2009-09-02 | 上海交通大学 | Hybridoma strain and preparation method thereof |
| CN102827826A (en) * | 2012-09-11 | 2012-12-19 | 赵永祥 | Method for inducing dendritic cells and tumour cells to fuse |
| CN105063013A (en) * | 2015-09-02 | 2015-11-18 | 北京多赢时代科技有限公司 | Fusion cell, preparation method of fusion cell and application of fusion cell as tumor vaccine |
| CN105316313A (en) * | 2015-11-03 | 2016-02-10 | 重庆市畜牧科学院 | Efficient cell fusion method |
| CN108315319A (en) * | 2018-02-05 | 2018-07-24 | 翁炳焕 | A kind of cell fusion method of CD138 monoclonal antibodies target capture |
Non-Patent Citations (1)
| Title |
|---|
| HENRY HARRIS等: "Suppression of Malignancy by Cell Fusion", NATURE, vol. 223, pages 363 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shah et al. | An injectable bone marrow–like scaffold enhances T cell immunity after hematopoietic stem cell transplantation | |
| Yu et al. | Sulfated polysaccharide directs therapeutic angiogenesis via endogenous VEGF secretion of macrophages | |
| SykovÁ et al. | Magnetic resonance tracking of implanted adult and embryonic stem cells in injured brain and spinal cord | |
| Ryan et al. | Chondrogenic differentiation increases antidonor immune response to allogeneic mesenchymal stem cell transplantation | |
| Sarkar et al. | Chemical engineering of mesenchymal stem cells to induce a cell rolling response | |
| US5192537A (en) | Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine | |
| JP2018080201A (en) | Combination therapy for stable and long term engraftment using a specific protocol for t cell/b cell depletion | |
| CN111603454A (en) | Multi-targeting fusion cell membrane modified bionic nano delivery system and preparation method and application thereof | |
| Park et al. | Etanercept-synthesising mesenchymal stem cells efficiently ameliorate collagen-induced arthritis | |
| Cherubino et al. | Human adipose-derived stem cells promote vascularization of collagen-based scaffolds transplanted into nude mice | |
| JPH11501656A (en) | How to treat a tumor | |
| JP2023171734A (en) | Immunoprivileged bioactive renal cells for treatment of kidney disease | |
| Zhang et al. | Particle-based artificial three-dimensional stem cell spheroids for revascularization of ischemic diseases | |
| Ma et al. | Applications of extracellular vesicles in tissue regeneration | |
| CN104470529A (en) | Treatment of radiation injury using amnion derived adherent cells | |
| CN113136362A (en) | Vesicle and application thereof | |
| CN110049771A (en) | The excretion body of cancer stem cell | |
| Chen et al. | Directional homing of glycosylation-modified bone marrow mesenchymal stem cells for bone defect repair | |
| Doloff et al. | Identification of a humanized mouse model for functional testing of immune-mediated biomaterial foreign body response | |
| Wang et al. | In vitro performance of an injectable hydrogel/microsphere based immunocyte delivery system for localised anti-tumour activity | |
| CN111902533A (en) | Method for producing natural killer cells | |
| CN106390123B (en) | MiR-29 and its inhibitor are preparing the application in anti-organ-graft refection's drug | |
| Wang et al. | Programming of regulatory T cells in situ for nerve regeneration and long-term patency of vascular grafts | |
| CN112195173A (en) | Method for fusing myocardial cells and tumor cells | |
| CN110564730B (en) | CD40L aptamer and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |